About the Company
Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications. Standard BioTools sells products to academic research institutions; translational research and medical centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology and plant and animal research companies; and contract research organizations.
Sector
Industrial Applications and Services
Industry
Laboratory Analytical Instruments
Employees
457
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on STANDARD BIOTOOLS INC.
Standard Biotools Inc. Faces Challenges in SomaScan Divestiture: Potential Risks and Strategic Imperatives
Standard Biotools Inc (LAB) has disclosed a new risk, in the Corporate Activity and Growth category. Standard Biotools Inc. faces significant ...
What to Expect from Standard BioTools Inc (LAB) Q2 2025 Earnings
Standard BioTools Inc (NASDAQ:LAB) is set to release its Q2 2025 earnings on August 11, 2025. The consensus estimate for Q2 ...
Standard BioTools Reports Second Quarter 2025 Financial Results
Standard BioTools Inc. (NASDAQ: LAB) (the 'Company” or 'Standard BioTools”) today announced financial results for the second ...
Standard BioTools Inc. (LAB) Q4 2023 Earnings Call Transcript
Standard BioTools Inc. (NASDAQ:LAB) Q4 2023 Results Conference Call February 28, 2024 4:30 PM ETCompany ParticipantsDavid Holmes - IRMichael Egholm - CEO ...
Standard BioTools Delays Quarterly Report Filing
Standard BioTools ( ($LAB) ) has released a notification of late filing. Standard BioTools Inc. has announced a delay in filing its Form 10-Q ...
Standard BioTools Inc. Announces Preliminary 2024 Revenue of ... - Nasdaq
Standard BioTools Inc. announced preliminary, unaudited revenue results for 2024, estimating approximately $174 million for the full year, with fourth quarter revenue expected to be around $46.5 ...
Standard BioTools: Q2 Earnings Snapshot
SOUTH SAN FRANCISCO, Calif. (AP) — Standard BioTools Inc. (LAB) on Monday reported a loss of $33.5 million in its second quarter.
Standard BioTools and SomaLogic Announce Date for Special Meetings of ...
Standard BioTools stockholders who need assistance voting or have questions regarding the Special Meeting may contact Standard BioTools’ proxy solicitor, Alliance Advisors LLC, at (800) 574-5969.
Standard BioTools Announces Preliminary Fourth Quarter and ... - Nasdaq
--Standard BioTools Inc., driven by a bold purpose– Unleashing tools to accelerate breakthroughs in human health, today announced Standard BioTools and SomaLogic, Inc. preliminary and unaudited ...
Standard BioTools Inc. (NASDAQ:LAB) Q4 2023 Earnings Call Transcript
Standard BioTools Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.13. LAB isn’t one of the 30 most popular stocks among hedge funds at the end of the third ...
Standard BioTools Inc. (NASDAQ:LAB) Q1 2024 Earnings Call Transcript
Standard BioTools Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome to the Standard BioTools Inc.
Similar Companies
Loading the latest forecasts...